2. Antibody-drug Conjugate/ADC Related
  3. Antibody-Drug Conjugates (ADCs)
  4. Ladiratuzumab vedotin

Ladiratuzumab vedotin  (Synonyms: SGN-LIV1A)

Cat. No.: HY-P99683

Molarity Calculator

Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer.

For research use only. We do not sell to patients.

Ladiratuzumab vedotin Chemical Structure

Ladiratuzumab vedotin Chemical Structure

CAS No. : 1629760-29-7

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Ladiratuzumab vedotin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer[1][2][3][4].

In Vitro

Ladiratuzumab vedotin (LIV-1+ cells) activates the ER stress response via the activation of ATF6 and phosphorylation of IRE1 and eIF2a[3].
Ladiratuzumab vedotin (LIV-1+ cells) releases ATP and HMGB1 into the supernatant (hallmarks of ICD[3].
Ladiratuzumab vedotin (0-100 ng/mL) shows cytotoxic activity against MCF-7 cell line[4].
Ladiratuzumab vedotin (1 μg/mL, 24 h) internalizes, traffics to the lysosome, and disrupts the microtubule network in MCF-7 cells[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ladiratuzumab vedotin Related Antibodies

Cell Viability Assay[4]

Cell Line: MCF-7
Concentration: 0-100 ng/mL
Incubation Time: 96 h
Result: Inhibited cell viability with an EC50 value of 6.3 ng/mL.
In Vivo

Ladiratuzumab vedotin (3 mg/kg, i.p., every 4 days) results tumor regression in MCF-7 breast cancer cell xenograft model[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MCF-7 breast cancer cell xenograft model[4]
Dosage: 3 mg/kg
Administration: i.p., every 4 days
Result: Delayed tumor growth.
Animal Model: BALB/C mice (PK assay)[4]
Dosage: 3 mg/kg
Administration: i.v., single
Result: Showed a terminal half-life of 6.8 days.
CAS No.
SMILES

[Ladiratuzumab vedotin]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ladiratuzumab vedotin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ladiratuzumab vedotin1629760-29-7SGN-LIV1AAntibody-Drug Conjugates (ADCs)Antibody-Drug ConjugatesBreast cancerMCF-7ER stressICDimmune responselysosomeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ladiratuzumab vedotin
Cat. No.:
HY-P99683
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.